Evidence map›Paper›PMID 29795309›Full record

ArticleBritish journal of cancer2018

Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams).

Christian Grønhøj, David H Jensen, Christian Dehlendorff, Linda Marklund, Steffen Wagner, Hisham Mehanna, Eva Munck-Wikland, Torbjörn Ramqvist, Anders Näsman, Claus Wittekindt and 15 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Type I conventional dendritic cells and CD8Frontiers in immunology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 4 countries.

Christian GrønhøjDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
David H JensenDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Christian DehlendorffStatistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark.
Linda MarklundDepartment of Clinical Science and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Steffen WagnerDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.
Hisham MehannaHead and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Eva Munck-WiklandDepartment of Clinical Science and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Torbjörn RamqvistDepartment of Clinical Science and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Anders NäsmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Claus WittekindtDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.
Nora WürdemannDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.
Shachi Jenny SharmaDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.
Stefan GattenlöhnerDepartment of Pathology, University of Giessen, Giessen, Germany.
Katalin KissDepartment of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Elo AndersenDepartment of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Rachel SpruceHead and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Nikos BatisHead and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
Max RobinsonCentre for Oral Health Research, Newcastle University, Newcastle, UK.
Kevin HarringtonThe Institute of Cancer Research/The Royal Marsden NIHR Biomedical Research Centre, London, UK.
Stuart WinterDepartment of Otorhinolaryngology, Head and Neck Surgery, Nuffield Department of Medicine, Oxford, UK.
Terence M JonesInstitute of Translational Medicine, University of Liverpool, Liverpool, UK.
Jens Peter KlussmannDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany.
Tina DalianisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jeppe FriborgDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Christian von BuchwaldDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. christian.buchwald@regionh.dk.
Karolinska Institutet · SEUniversity of Giessen · DERigshospitalet · DKUniversity of Birmingham · GBUniversity of Copenhagen · DKDanish Cancer Society · DKGiessen School of Theology · DENewcastle University · GBNuffield Orthopaedic Centre · GBRoyal Marsden Hospital · GBUniversity of Liverpool · GB

Funding

Medical Research Council MR/N005872/1
6 · The paper itself

Abstract

backgroundThe proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead to misallocation of patients. We established nomograms for overall survival (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and known HPV-DNA and p16 status, and validated the models in cohorts from high- and low-prevalent HPV countries.

methodsConsecutive OPSCC patients treated in Denmark, 2000-2014 formed the development cohort. The validation cohorts were from Sweden, Germany, and the United Kingdom. We developed nomograms by applying a backward-selection procedure for selection of variables, and assessed model performance.

resultsIn the development cohort, 1313 patients, and in the validation cohorts, 344 German, 503 Swedish and 463 British patients were included. For the OS nomogram, age, gender, combined HPV-DNA and p16 status, smoking, T-, N-, and M-status and UICC-8 staging were selected, and for the PFS nomogram the same variables except UICC-8 staging. The nomograms performed well in discrimination and calibration.

conclusionsOur nomograms are reliable prognostic methods in patients with OPSCC. Combining HPV DNA and p16 is essential for correct prognostication. The nomograms are available at www.orograms.org .

Indexed as

NomogramsAgedCohort StudiesDenmarkDNA, ViralFemaleGermanyHumansMaleMiddle AgedOropharyngeal NeoplasmsPapillomaviridaeReproducibility of ResultsSquamous Cell Carcinoma of Head and NeckSwedenUnited KingdomDNA, Viral

Identifiers

PMID29795309
PMCPMC6008433
OpenAlexW2805002956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.